These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

85 related items for PubMed ID: 9025162

  • 21. [The use of anagrelide to treat thrombocytosis in connection with the chronic myeloproliferative disease].
    Jantunen E, Penttilä K, Kuittinen T, Nousiainen T.
    Duodecim; 2006; 122(4):453-7. PubMed ID: 16623100
    [No Abstract] [Full Text] [Related]

  • 22. Successful treatment of essential thrombocythemia with anagrelide in a child.
    Hermann J, Fuchs D, Sauerbrey A, Hempel L, Zintl F.
    Med Pediatr Oncol; 1998 Jun; 30(6):367-70; discussion 370-1. PubMed ID: 9589087
    [No Abstract] [Full Text] [Related]

  • 23. [Anagrelide--a new drug to reduce platelets in myeloproliferative diseases].
    Bennett M.
    Harefuah; 1999 May 02; 136(9):717-20. PubMed ID: 10955097
    [No Abstract] [Full Text] [Related]

  • 24. Anagrelide for essential thrombocythemia.
    Med Lett Drugs Ther; 1997 Dec 19; 39(1016):120. PubMed ID: 9422046
    [No Abstract] [Full Text] [Related]

  • 25. The combined use of hydroxyurea and anagrelide allows satisfactory hematologic control in patients with chronic myeloproliferative disorders and thrombocytosis: a report on 13 patients with poor tolerance to hydroxyurea monotherapy.
    D'adda M, Micheletti M, Drera M, Ferrari S, Rossi G.
    Leuk Lymphoma; 2008 Nov 19; 49(11):2216-8. PubMed ID: 19021067
    [No Abstract] [Full Text] [Related]

  • 26. [Essential thrombocytemia and other myeloproliferations with thrombocytemia in the data of the register of patients treated with Thromboreductin till the end of 2006].
    Penka M, Schwarz J, Pavlík T, Pytlík R, Doubek M, Dulícek P, Pospísilová D, Kissová J, Hlusí A, Schützová M, Cerná O, Brychtová Y, Szotkowski T, Volková Z, Seghetová J, Vozobulová V, Hadacová I, Hochová I, Voglová J, Lhotanová T, Bubeník B, Zapletal O, Vránová M, Micaníková M, Dusek L.
    Vnitr Lek; 2007 Jun 19; 53(6):653-61. PubMed ID: 17702125
    [Abstract] [Full Text] [Related]

  • 27. [Essential thrombocythemia as a cause of headache in young woman].
    Bieniaszewska M, Balon J, Hellmann A.
    Pol Merkur Lekarski; 2000 Jul 19; 8(49):479-80. PubMed ID: 11070720
    [Abstract] [Full Text] [Related]

  • 28. Effect of anagrelide on platelet count and function in patients with thrombocytosis and myeloproliferative disorders.
    Balduini CL, Bertolino G, Noris P, Ascari E.
    Haematologica; 1992 Jul 19; 77(1):40-3. PubMed ID: 1398280
    [Abstract] [Full Text] [Related]

  • 29. Successful outcome with anagrelide in pregnancy.
    Alkindi S, Dennison D, Pathare A.
    Ann Hematol; 2005 Oct 19; 84(11):758-9. PubMed ID: 15959777
    [No Abstract] [Full Text] [Related]

  • 30. Therapy with Anagrelide in patients affected by essential thrombocythemia: preliminary results.
    Mazzucconi MG, De Sanctis V, Chistolini A, Dragoni F, Mandelli F.
    Haematologica; 1992 Oct 19; 77(4):315-7. PubMed ID: 1427441
    [Abstract] [Full Text] [Related]

  • 31. Primary thrombocythemia: a current perspective.
    Mughal TI.
    Stem Cells; 1995 Jul 19; 13(4):355-9. PubMed ID: 7549894
    [Abstract] [Full Text] [Related]

  • 32. Anagrelide as a new platelet-lowering agent in essential thrombocythemia: mechanism of actin, efficacy, toxicity, current indications.
    Tefferi A, Silverstein MN, Petitt RM, Mesa RA, Solberg LA.
    Semin Thromb Hemost; 1997 Jul 19; 23(4):379-83. PubMed ID: 9263355
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Safety profile of hydroxyurea in the treatment of patients with Philadelphia-negative chronic myeloproliferative disorders.
    Randi ML, Ruzzon E, Luzzatto G, Tezza F, Girolami A, Fabris F.
    Haematologica; 2005 Feb 19; 90(2):261-2. PubMed ID: 15710584
    [Abstract] [Full Text] [Related]

  • 35. Treatment of essential thrombocythemia with anagrelide.
    Silverstein MN, Tefferi A.
    Semin Hematol; 1999 Jan 19; 36(1 Suppl 2):23-5. PubMed ID: 9930554
    [Abstract] [Full Text] [Related]

  • 36. 6-Thioguanine treatment of uncontrolled thrombocytosis in polycythemia vera and essential thrombocythemia.
    Delfini C, Porcellini A, Izzi T, Baronciani D.
    Haematologica; 1984 Jan 19; 69(6):766-7. PubMed ID: 6441754
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Aspirin-responsive painful red, blue, black toe, or finger syndrome in polycythemia vera associated with thrombocythemia.
    Michiels JJ, Berneman Z, Schroyens W, van Urk H.
    Ann Hematol; 2003 Mar 19; 82(3):153-9. PubMed ID: 12634947
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 5.